PDCD1 and non-small cell lung carcinoma: In pretreated NSCLC patients, HPD is more common with PD-1/PD-L1 inhibitors compared to chemotherapy, and patients treated with PD-1/PD-L1 inhibitors are also associated with a high metastatic burden and poor prognosis (73).